Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing
December 10 2018 - 4:30PM
Business Wire
Regulatory News:
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a
biopharmaceutical company focused on developing immunotherapies
based on gene-edited CAR T-cells (UCART), today announced the
appointment of William (Bill) Monteith to the role of Senior Vice
President U.S. Manufacturing. This appointment follows Cellectis’
plan to establish commercial manufacturing capabilities in the
U.S., which will be Bill Monteith’s responsibility, notably through
the deployment of a proprietary state-of-the-art gene-edited cell
manufacturing plant for clinical and commercial supplies of our
current immuno-oncology UCART product candidates.
Bill Monteith joins Cellectis from Hitachi Chemical Advanced
Therapeutics Solutions, where he was the Chief Operating Officer
and Site General Manager for three manufacturing facilities. Bill
Monteith is based in our New York office and reports to David
Sourdive, Ph.D., Co-founder of Cellectis and Executive Vice
President Technical Operations.
“With over 35 years of experience in manufacturing, operations
and quality assurance, Bill brings his expertise and strategic
capabilities to Cellectis at a crucial time, as the company now has
two wholly-controlled product candidates being tested in clinical
trials, with more to come in 2019,” said Dr. André Choulika,
Cellectis Chief Executive Officer. “I am confident that Bill will
be a major addition to our team and a driving force as we
accelerate our transformation into a fully-fledged
biopharmaceutical company, move forward our off-the-shelf,
gene-edited CAR T-cell product candidates and continue our
commitment to a cure for cancer patients.”
Bill joins Cellectis as a recognized global operations leader
with deep manufacturing expertise from his prior roles at various
pharmaceutical companies. Prior to his position at Hitachi, Bill
spent over 5 years honing his craft at Dendreon Pharmaceuticals,
where he held the roles of Vice President and General Manager and
later, Executive Vice President Technical Operations. Bill has also
held positions with Sandoz Pharmaceuticals, Shire Pharmaceuticals
and Wyeth Pharmaceuticals, playing a crucial part in their
respective manufacturing processes.
“This is a pivotal time for Cellectis, as we continue clinical
trials and shift closer to product commercialization – something
that will ultimately have the potential to impact patients,” noted
Mr. Monteith. “I am eager to hit the ground running and begin
implementing with a team that has already done so much to build a
strong and efficient manufacturing process, and am honored to be a
part of the company that’s pioneering the allogeneic CAR T-cell
space.”
About Cellectis
Cellectis is a clinical-stage biopharmaceutical company focused
on developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 18 years of
expertise in gene editing – built on its flagship TALEN® technology
and pioneering electroporation system PulseAgile – Cellectis uses
the power of the immune system to target and eradicate cancer
cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq (ticker: CLLS) and on Euronext
Growth (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by Cellectis.
Disclaimer
This press release contains “forward-looking” statements that
are based on our management’s current expectations and assumptions
and on information currently available to management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Further information on the risk
factors that may affect company business and financial performance
is included in Cellectis’ Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2017 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181210005824/en/
For further information, please contact:
Media contacts:Jennifer Moore, VP of Communications,
917-580-1088, media@cellectis.comCaitlin Kasunich, KCSA Strategic
Communications, 212-896-1241, ckasunich@kcsa.com
IR contact:Simon Harnest, VP of Corporate Strategy and
Finance, 646-385-9008, simon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2023 to Apr 2024